Soluble Fas ligand expression in the ocular fluids of uveitis patients

Current Eye Research

Volumn 20, Issue 1, 2000, Pages 54-57

  Sotozono, Chie ^a   Sano, Yoichiro ^a   Suzuki, Tomo ^a   Tada, Rei ^a   Ikeda, Tsunehiko ^a   Nagata, Shigekazu ^b   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Aqueous humor; Fas ligand; Uveitis; Vitreous fluid

Indexed keywords

FAS LIGAND;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; EYE INFLAMMATION; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; UVEITIS; VITREOUS BODY;

EID: 0033981405     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/0271-3683(200001)2011-HFT054     Document Type: Article

References (25)

1. Nagata S and Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
2. Suda T, Takahashi T, Golstein P, and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75: 1169-1178.
3. Gruss HJ and Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378-3404.
4. Smith CA, Farrah T, and Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962.
5. Nagata S and Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16:39-43.
6. Rouvier E, Luciani MF, and Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993;177:195-200.
7. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, and Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-3813.
8. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, and Golstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med. 1995;181:781-786.
9. Watanabe FR, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, and Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992;148:1274-1279.
10. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten EC. Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, and Black RA. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218-220.
11. McGeehan GM, Becherer JD, Bast RJ, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994;370:558-561.
12. Tanaka M, Suda T, Takahashi T, and Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. Embo J. 1995;14:1129-1135.
13. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, and Nagata S. Fas ligand in human serum. Nat Med. 1996;2:317-322.
14. Griffith TS, Yu X, Herndon JM, Green DR, and Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
15. Griffith TS, Brunner T, Fletcher SM, Green DR, and Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
16. Hunt JS, Vassmer D, Ferguson TA, and Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol. 1997;158:4122-4128.
17. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, and Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
18. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, and Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
19. Bloch ME and Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987; 103:234-235.
20. Chan CC, Matteson DM, Li Q, Whitcup SM, and Nussenblatt RB. Apoptosis in patients with posterior uveitis. Arch Ophthalmol. 1997;115:1559-1567.
21. Wilson SE, Li Q, Weng J, Barry LP, Jester JV, Liang Q, and Wordinger RJ. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci. 1996;37:1582-1592.
22. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, and Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996; 184:429-440.
23. Tortorella C, Piazzolla G, Spaccavento F, Pece S, Jirillo E, and Antonaci S. Spontaneous and Fas-induced apoptotic cell death in aged neutrophils. J Clin Immunol. 1998;18:321-329.
24. Suda T, Hashimoto H, Tanaka M, Ochi T, and Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045-2050.
25. Tanaka M, Itai T, Adachi M, and Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36.